KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Net Margin (2023 - 2025)

Biocryst Pharmaceuticals' Net Margin history spans 9 years, with the latest figure at 34723.87% for Q4 2025.

  • For Q4 2025, Net Margin rose 3474424.0% year-over-year to 34723.87%; the TTM value through Dec 2025 reached 56.26%, up 7598.0%, while the annual FY2025 figure was 30.16%, 4988.0% up from the prior year.
  • Net Margin reached 34723.87% in Q4 2025 per BCRX's latest filing, up from 8.09% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 34723.87% in Q4 2025 to a low of 52.41% in Q4 2023.
  • Average Net Margin over 3 years is 3844.51%, with a median of 11.59% recorded in 2024.
  • The largest YoY upside for Net Margin was 3474424bps in 2025 against a maximum downside of 1471bps in 2025.
  • A 3-year view of Net Margin shows it stood at 52.41% in 2023, then surged by 61bps to 20.37% in 2024, then surged by 170556bps to 34723.87% in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Net Margin are 34723.87% (Q4 2025), 8.09% (Q3 2025), and 3.11% (Q2 2025).